• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

TIMs make impact on infants

Winston-Salem, N.C. - Separate studies involving atopic dermatitis drugs tacrolimus (Protopic) and pimecrolimus (Elidel) show the topical immunomodulators (TIMs) are safe and effective for off-label use on children under age 2.

Related Videos
Related Content
Johnson & Johnson Submits 2 sBLAs for Guselkumab for Pediatric Psoriasis and Juvenile PsA
December 2nd 2024

Johnson & Johnson Submits 2 sBLAs for Guselkumab for Pediatric Psoriasis and Juvenile PsA

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
August 1st 2023

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

Shanna Miranti, MPAS, PA-C, Shares Expert Acne and Pediatric Dermatology Insights
November 17th 2024

Shanna Miranti, MPAS, PA-C, Shares Expert Acne and Pediatric Dermatology Insights

The Cutaneous Connection
August 5th 2021

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

Elimination Diets Have Little Impact on Pediatric Atopic Dermatitis, New Study Finds
October 24th 2024

Elimination Diets Have Little Impact on Pediatric Atopic Dermatitis, New Study Finds

Combination of Abrocitinib and Dupilumab Effectively Treats Pediatric Atopic Dermatitis
October 17th 2024

Combination of Abrocitinib and Dupilumab Effectively Treats Pediatric Atopic Dermatitis

© 2024 MJH Life Sciences

All rights reserved.